Genmab (CPH:GEN)

SeekingAlpha  May 10  Comment 
FiercePharma  Apr 4  Comment 
Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma chelfand Tue, 04/04/2017 - 09:06
GenEng News  Mar 31  Comment 
Johnson & Johnson's Janssen Biotech will not proceed with stage 2 of the Phase II CARINA LYM2001 trial assessing the marketed cancer drug Darzalex ® (daratumumab) in three types of relapsed or refractory non-Hodgkin’s lymphoma (NHL), J&J’s...
SeekingAlpha  Feb 22  Comment  Jan 12  Comment 
NEW BRUNSWICK (dpa-AFX) - Genmab A/S (GMXAY.PK, GNMSF.OB) said that worldwide net sales of Darzalex, or daratumumab, as reported by Johnson & Johnson (JNJ) were $572 million in 2016. This comprised of net sales of $471 million in the U.S. and net...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki